CAMBRIDGE, Mass., Nov. 02, 2016 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA ), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced the appointment of Scott M. Storer as Senior Vice President and Chief Financial Officer. Mr. Storer is expected to begin at Momenta on November 28, 2016 and will replace Momenta’s current Chief Financial Officer, Rick Shea, who will be retiring. Mr. Storer will report directly to Craig Wheeler, Momenta’s President and Chief Executive Officer, and will serve as a member of the Executive Committee.
“I am very pleased to have Scott join Momenta. He has a great track record across his 20 years with Baxter and Baxalta, and I believe his expertise in financial planning and leading global strategic growth initiatives and operations will benefit Momenta tremendously,” said Craig Wheeler, President and CEO, Momenta Pharmaceuticals. “With the addition of Scott’s leadership, I look forward to continuing to advance the development and commercialization of our robust portfolio of biosimilar and novel drug candidates.”
Prior to joining Momenta, Mr. Storer was Senior Vice President, Finance at Baxalta, Inc. following its spin-out from Baxter International in July 2015. Previously, Mr. Storer held several positions with Baxter, most recently serving as Vice President of BioScience Finance where he provided financial leadership, internal controls and business partnership to the BioScience US commercial organization, global manufacturing, R&D, business development and all support functions. Before that he held positions of increasing responsibility at several of Baxter’s international finance divisions. Mr. Storer began his work at Baxter as a financial analyst in 1997. He received a Master’s in Business Administration from Northwestern University’s Kellogg School of Management and a Bachelor of Science degree in business administration from the University of Colorado at Boulder.
About Momenta Momenta Pharmaceuticals is a biotechnology company specializing in the detailed structural analysis of complex drugs and is headquartered in Cambridge, MA. Momenta is applying its technology to the development of generic versions of complex drugs, biosimilar and potentially interchangeable biologics, and to the discovery and development of novel therapeutics for autoimmune indications.
To receive additional information about Momenta, please visit the website at www.momentapharma.com , which does not form a part of this press release.
Our logo, trademarks, and service marks are the property of Momenta Pharmaceuticals, Inc. All other trade names, trademarks, or service marks are property of their respective owners.
Forward Looking Statements
Statements in this press release regarding management's future expectations, beliefs, intentions, goals, strategies, plans or prospects, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including but not limited to statements about Mr. Storer’s expected start date and the expected benefits from his service to the Company. Forward-looking statements may be identified by words such as "anticipate," "believe," "continue," "could," "hope," "target," "project," "goal," "objective," "guidance," "plan," "potential," "predict," "might," "estimate," "expect," "intend," "may," "seek", "should," "will," "would," "look forward" and other similar words or expressions, or the negative of these words or similar words or expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, including those referred to under the section "Risk Factors" in the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2016, filed with the Securities and Exchange Commission, as well as other documents that may be filed by the Company from time to time with the Securities and Exchange Commission. As a result of such risks, uncertainties and factors, the Company's actual results may differ materially from any future results, performance or achievements discussed in or implied by the forward-looking statements contained herein. The Company is providing the information in this press release as of this date and assumes no obligations to update the information included in this press release or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
INVESTOR CONTACT: Sarah Carmody Momenta Pharmaceuticals 1-617-395-5189 IR@momentapharma.com MEDIA CONTACT: Karen Sharma MacDougall Biomedical Communications 1-781-235-3060 Momenta@macbiocom.com
